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Background: Melanoma aggressiveness determines its growth and metastatic potential. This study aimed at
identifying new molecular pathways controlling melanoma cell malignancy.
Methods: Ten metastatic melanoma cell lines were characterized by their proliferation, migration and invasion
capabilities. The most representative cells were also characterized by spheroid formation assay, gene- and
protein- expression profiling as well as cytokines secretion and the most relevant pathways identified through
bioinformatic analysis were tested by in silico transcriptomic validation on datasets generated from biopsies
specimens of melanoma patients. Further, matrix metalloproteases (MMPs) activity was tested by zymography
assays and TNF-alpha role was validated by anti-TNF cell-treatment.
Results: An aggressiveness score (here named Melanoma AGgressiveness Score: MAGS) was calculated by
measuring proliferation, migration, invasion and cell-doubling time in10human melanoma cell lines which
were clustered in two distinct groups, according to the corresponding MAGS. SK-MEL-28 and A375 cell lines
were selected as representative models for the less and the most aggressive phenotype, respectively. Gene-
expression and protein expression data were collected for SK-MEL-28 and A375 cells by Illumina-, multiplex
x-MAP-and mass-spectrometry technology. The collected data were subjected to an integrated Ingenuity
Pathway Analysis, which highlighted that cytokine/chemokine secretion, as well as Cell-To-Cell Signaling and
Interaction functions as well as matrix metalloproteases activity were significantly different in these two cell
types. The key role of these pathways was then confirmed by functional validation. TNF role was confirmed
by exposing cells to the anti-TNF Infliximab antibody. Upon such treatment melanoma cells aggressiveness
was strongly reduced. Metalloproteases activity was assayed, and their role was confirmed by comparing
transcriptomic data from cutaneous melanoma patients (n = 45) and benign nevi (n = 18).
Conclusions: Inflammatory signals such as TNF and MMP-2 activity are key intrinsic players to determine
melanoma cells aggressiveness suggesting new venue sin the identification of novel molecular targets with
potential therapeutic relevance.
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Melanoma incidence and mortality are steeply increased
in the last century [1–3]. Melanoma is the most aggressive
skin cancer and the cutaneous form (Cutaneous Melan-
oma, CM) is the most common one. Recent data on novel
pathways involved in melanoma development opened new
opportunities to identify novel therapeutic targets [4, 5],
nevertheless additional key players underlying melanoma
onset and progression need to be identified. Indeed, fur-
ther elucidation of the molecular mechanisms underlying
melanoma malignancy is expected to improve prognostic
assessment and therapeutic options. The role of altered
RAS/BRAF/MEK/ERK pathway in melanoma patho-
genesis and progression is well known [6]. Mutated
BRAFV600E represents a major target in the current
therapeutic strategies, despite the fact that more than
half of melanomas do not harbor this mutation. Mel-
anoma highly aggressive behavior depends on migra-
tion, invasion, proliferation of metastatic cells and on
their ability to promote angiogenesis [7]. Invasive CM
cells metastasize changing cytoskeletal organization
and modifying the interaction with the extracellular
matrix (ECM) and the surrounding stromal cells. During
the vertical growth phase, primary tumor cells invade the
dermis [8], via a cross-talk with the neighboring micro-
environment [9, 10]. Proteolysis in the pericellular and
stromal compartments, in fact, exerts a key role in the in-
vasion process and it is well know that several protease,
such as matrix metalloproteases (MMPs), are mediators of
melanoma development [11]. On the other hand, MMP-9
activation was associated with cancer growth and dissem-
ination [12], its role in cutaneous melanoma was reported
and its activation, mediated by NF-κB, was associated with
the BRAFV600E mutation status [13]. Another recent
study reports the correlation of MMP-9 hypermethylation
with its overexpression in melanoma [14] indicating novel
molecular mechanisms underlying the MMPs activity and
their modulatory role in melanoma aggressiveness.
Different molecules play a role in cancer progression,
including chemokines and their receptors, as well as cy-
tokines and growth factors [15]. Melanoma cells often
express variable levels of cytokines and cytokine recep-
tors at different stages of disease progression. Interleukin
(IL-)1β, IL-6 and IL-8, for example, are known to be im-
portant drivers of cell proliferation and melanoma pro-
gression [16, 17]. Nevi and thin primary melanomas
(less than < 1mm of thickness) express low levels of
IL-8, tumor necrosis factor-alpha (TNF-α), transforming
growth factor-beta (TGF-β) and c-kit [18]. On the con-
trary, primary melanomas at more advanced stage (> 1
mm of thickness) show up-regulation of IL-1α, IL-1β,
IL-8, TNF-α, TGF-β and granulocyte-macrophage colony
stimulating factor (GM-CSF). TGF-β is considered a
marker of melanoma metastatic spreading [18]. Moreover,a link between high levels of TNF-α and increased risk
of tumor formation and development has been de-
scribed in vivo [19]. An additional study in a murine
model shows that more aggressive tumors express
lower levels of TNF-α and other inflammatory cyto-
kines, as determined by qRT-PCR analyses [20], con-
firming previously reported controversial role of TNF-α
[21]. This suggests that melanoma development and
progression is a complex process based on a well-
organized interplay of intrinsic proliferation ability
combined to the immune and angiogenic response, as
coordinated action of several cell types. Cytokines con-
trolling inflammation and immune cells can influence
host immune response and melanoma cells can activate
and/or reshape the surrounding environment to secrete
factors mediating metastatic progression. Furthermore,
melanoma cells can secrete inhibitory modulators and
thereby arrest recognition and maturation of effector
immune cells [22] or other signals affecting cancer cells
microenvironments [23]. Therefore, several different
mechanisms control CM ability to rapidly grow, invade
and disseminate metastases in other tissues and organs.
This highlights the importance of microenvironment
and immune response to CM, as strongly influenced by
intrinsic characters of primary melanoma cells.
Understanding such multifaceted functional interac-
tions, involving different cell types and molecules, re-
quires to integrate information gathered by different
analytical approaches [24–26]. The aim of the present
study was to investigate intrinsic factors affecting human
melanoma cell aggressiveness, investigating at different
levels human melanoma cells that hold highly different
malignancy grade. The study led to the novel identifica-
tion of molecular targets and functional pathways likely
responsible of the melanoma aggressive phenotype.
Methods
Experimental design and cell culture
The aggressive phenotype of CM is responsible for the
very poor prognosis of this disease as in advanced or in
recurrent cases [1]. CM aggressiveness has been associ-
ated with its mutational state (e.g. to bear or not a
V600E BRAF mutation, alone or together with others),
and also with the anatomical site where the primary
tumor occurs or, in addition, with the immunological
status of patients observed in different cases of patients
receiving immunosuppressive therapies [27, 28]. Beside
these considerations, one crucial question is whether
such melanoma cell aggressiveness may be explained
also by the presence of any intrinsic behavior of melan-
oma cell itself.
Human melanoma cells expressing different aggressive-
ness were therefore compared under very similar culture
conditions (melanocytes were not included in this study
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used for their in vitro culture; see Additional file 1:
Table S1).
Ten human cell lines were used, as summarized in
Table 1. Human metastatic cutaneous melanoma cell
lines used were: SK-MEL-28, A375 and A375M (pur-
chased and authenticated from the American Type Cul-
ture Collection, ATCC, Manassas, VA), Mel-397 (kindly
supplied by Dr. Stefania D’Atri, IDI-Roma), SK-MEL-110
[29], Preyer, SK-MEL-30 and MEWO (kindly provided
by Dr. Tobias Haas, ISS, Rome) [30], MEL501 and
ME665 (kindly provided by Dr. Francesca Urbani, ISS-
Rome). Preliminary experiments included additional hu-
man melanoma cell lines such as WM-115, SK 120 and
SK 147 from established culture [31] and human uveal
melanoma cell lines as (92.1, OMM1, OMM 2.5 and
UPMM3, kindly provided by Dr. Giovanna Angelini, IST,
Genova, Italy) [32]. All cell lines were cultured in the
specific standard conditions following the manufacturer’s
instructions or as previously reported [33, 34]. In detail,
A375, Preyer, SK-MEL-30, MEWO, MEL501 and ME665
were propagated in complete Dulbecco’s modified Eagle’s
medium (DMEM; Hyclone, South Logan, UT) supple-
mented with 10% fetal bovine serum (FBS, HyClone), 2
mM L-glutamine and 100 IU/ml penicillin/streptomycin
(Invitrogen, Carlsbad, CA) in humidified 5% CO2 atmos-
phere, at 37 °C for the specified time and, when required,
under serum deprivation. Mel 397, SK-MEL-28 and SK-
Mel-110 were cultured in RPMI 1640 (Hyclone) 10%
Fetal Calf Serum (FCS), 2 mM L-glutamine, and 100 IU/
ml penicillin/streptomycin and, when required, under
serum deprivation.
Proliferation assay
Proliferation assays were carried out as previously de-
scribed [26]. Briefly, cells (6 × 104 cells/well) were seeded
in 6-well plates and grown for24 h in the presence of
10% FCS and then grown for 24 h and/or 48 h inTable 1 Human melanoma cell lines used in the present study, with
Mutant Gene Gene Sequence
A375 BRAF CDKN2A CDKN2A c.1799 T > A c.181G > T c.205G
A375M BRAF c.1799 T > A
ME 665 NRAS c.182A > G
Mel 397 BRAF
MEL 501 NRAS BRAF c.35G > A c.1799 T > A
MeWo CDKN2A TP53 TP53 c.238C > T c.772G > A c.949C >
Preyer n/a n/a
SK-MEL-110 TP53 n/a
SK-MEL-28 BRAF TP53 CDK4 c.1799 T > A c.434 T > C c.70C
SK-MEL-30 NRAS CDKN2A c.181C > A c.341C > T
The asterisks refer to the mutations as reported onto the ATCC catalogserum-free medium. Subsequently, cells were washed
using phosphate buffer saline (PBS w/o Ca2+/Mg2+), har-
vested with trypsin/EDTA and counted with a Neubauer
modified chamber as previously reported [26]. To inves-
tigate the cell-cell signaling and interaction, additional
proliferation assays at three different cell-densities were
carried out, namely high (9x104cells/well), intermediate
(6 × 104 cells/well) and low (3 × 104 cells/well), following
the same experimental procedure reported above. All ex-
periments were performed at least 3 times in duplicate.
Spheroid formation assay
Spheroid formation assay was performed as previously
described [35]. Briefly, A375 and SK-MEL-28 cells
(5000cells/ml) were plated in ultralow attachment plates
(Corning, NY, USA) in a serum-free medium as described
[36]. Primary spheroids were collected after 7/14 days, dis-
sociated into single cell suspension, counted and plated
again in another ultralow attachment plate at 1000 cells/
ml density. After 7 days, secondary spheroids were photo-
graphed, dissociated into single cells and counted.
Cell migration and invasion assays
Cell migration assay was carried out by growing cells to
confluence in 12-well plates and wounds were made
with a sterile plastic tip as described [37]. Melanoma
cells were incubated for 24 h in the absence of FCS and
photographed under microscope at time 0 and after 24
h. The number of migrating cells was quantified by
Image J software (NIH: https://imagej.nih.gov/ij/) and
expressed as a percentage of control. Cell invasion ability
was tested using a commercial Transwell system
(24-well plates, 8.0 μm pore size, Corning, NY, USA).
Transwell upper inserts were coated with 0.1 ml of Bio-
Coat™ Matrigel™ and incubated overnight at 37 °C, then
0.2 ml warm (37 °C) serum-free medium was added to
melanoma cells (2 × 105) seeded into the upper wells of
24-well Transwell plates on Matrigel. Lower wellsreference to the mutational state
Protein Sequence PubMed ID
> T p. V600E p.E61* p.E69* 16,801,397 7,923,152
p. V600E 25,684,511
p.Q61R 8,032,213
p. V600E
p.G12D p.V600E 24,838,835 15,467,732
T p.R80* p.E258K p.Q317* 7,478,563 11,096,420
n/a n/a
n/a 16,267,831
> T p. V600E p. L145R p.R24C 16,170,021 23,856,246 23,856,246
p.Q61K p.P114L 10,766,161 8,895,759
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incubation in a humidified 5% CO2atmosphere, the
upper well content (non-invading cells) was removed,
the inserts were washed with PBS and cells were fixed
with absolute ethanol. The invasion chambers were
processed following the manufacturer’s protocols, and
cells were stained with 5% GIEMSA as described [38].
Cells were counted under phase-contrast microscopy.
To confirm data obtained by the Transwell model, inva-
siveness of melanoma cells was also evaluated in Boyden
Chamber assay as described [39], with polyvinylidene
difluoride (PVPF) membrane (8 μm pore size, Costar,
Cambridge, MA). The membrane was fixed in absolute
ethanol and stained with 5% GIEMSA. After removal of
non-migrating cells in the upper side of the membrane,
the number of invasive cells was calculated as the mean
of 8 microscopy-fields.
Calculation of the aggressiveness score
In order to develop a tool able to quantify melanoma
cell malignancy, the Melanoma cell AGgressiveness
Score (MAGS) was calculated. Such score was a quanti-
tative parameter obtained from the combination of pro-
liferation, migration and invasiveness ability of each
investigated melanoma cell. MAGS score was calculated
using the following algorithm:
MAGS ¼ GrowthMigration Invasion
Doubling time
were Growth is the percentage of proliferation after 24
h, Migration is the percentage of plate surface covered
by migrated cells after 24 h, Invasion is the percentage of
cells passing through the Transwell filter after 24 h (all
such parameters were compared to time zero), Doubling
time is the time cells use to double their number, com-
puted according to the last square fitting exponential
method expressed in hours.
Programmed cell death analysis
Cells cultured in 6-well plates (Corning, NY, USA) were
harvested, taking into account both floating and attached
cells, and fixed in 80% cold ethanol. Fixed cells were
washed and incubated with10 μg/ml propidium iodide
(PI) and 200 μg/ml ribonuclease A (RNAse A, Thermo
Fisher, MA,USA) as previously described [31]. The relative
DNA content and cells distribution in cell cycle phases
were determined with both FACScan Becton Dickinson
Instrument (Becton Dickinson, CA, USA) and the FACS
Diva software (5.0.3 version) as previously described [40].
Cytokines and growth factor analysis
Cytokines and growth factors were measured by xMAP
multiplex technology. Bio-Plex Pro human cytokine27-plex panel (Bio-Rad Laboratories, Hercules, CA)
allowed to measure the following analytes: IL-1Ra,
IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10,
IL-12(p70), IL-13, IL-15, IL-17, TNF-α, IFN-γ, Macro-
phage Inflammatory Protein (MIP)-1α, MIP-1β, Eotaxin,
Monocyte Chemoattractant (MCP)-1 (CCL2), Granulo-
cyte Colony stimulating factor (G-CSF), GM-CSF, Basic
Fibroblast growth factor (FGF-2), Vascular endothelial
growth factor (VEGF), Interferon gamma-induced pro-
tein 10 (IP-10), Regulated on Activation, Normal T cell
Expressed and Secreted (RANTES or CCL5), and
Platelet-derived growth factor (PDGF)-BB. Conditioned
media were collected, centrifuged and four-fold concen-
trated using a centrifugal filter unit trough microporous
membrane 3 kDa cut-off (Centriprep YM-3, NMWL 3
kDa, Merck KGaA, Darmstadt, Germany). Proteins con-
centration was then measured using the Bradford assay
(Bio-Rad) according to manufacturer’s instructions. Add-
itional experiments were carried out by measuring cyto-
kines level into cell lysates, prepared as previously
reported [26]. The analysis was carried out using 50 μl of
sample. After incubation with antibodies-activated mag-
netic beads, samples were washed using a Bio-Plex Pro™
Station (Bio-Rad). The quantification was carried out on
a Luminex X200 platform (Bio-Plex® Bio-Rad), a Bio-
Plex Manager Software version 6.1 and results were
expressed as pg/ml/mg of protein. Protein concentration
was evaluated according to the Bradford assay (Bio-Rad).
Each sample was analysed at least three times in duplicate.
Data are expressed as mean ± standard deviation (SD).
RNA purification, gene expression microarray and data
analysis
After medium removal, cells were harvested and lysed in
TRIzol reagent (Invitrogen Corporation, Carlsbad, CA,
USA). Total RNA was then isolated from the samples fol-
lowing the manufacturer’s instructions. Before use, RNA
concentration in each sample was assayed with NanoDrop
2000C spectrophotometer (NanoDrop, Thermo Scientific,
Rockford, IL) and its quality was assessed with an Agilent
2100 Bioanalyzer with the Agilent RNA 6000 nano kit
(Agilent Technologies, Santa Clara, CA) as previously de-
scribed [41]. mRNA microarrays analyses were performed
using 500 ng of total RNA as starting material for the syn-
thesis of cDNA and biotinylated cRNA, according to the
Illumina Total Prep RNA Amplification Kit protocol
(Ambion, Austin, TX,). For each sample, 750 ng of cRNA
were hybridized on Illumina HumanHT-12 v 4.0 Bead-
Chips (Illumina Inc.) as described earlier [42] and subse-
quently scanned with the Illumina iSCAN. Data analyses
were performed with Genome Studio software version
2011.1 (Illumina Inc.). Data were normalized with the
quantile algorithm, and genes were considered detected if
the detection p-value was less than 0.01. Statistical
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proprietary algorithm that uses the bead standard devi-
ation to build an error model. Only genes with a Diff-
Score of - ≤30 or ≥ 30, corresponding to a p-value of
0.001, were considered as statistically significant by
comparing all values obtained in A375 cells compared
to the SK-MEL-28 values. Raw and quantile normalized
microarray data have been deposited, in a format com-
plying with the Minimum Information about a Micro-
array Gene Experiment guidelines of the Microarray
Gene Expression Data Society, in the EBI Array- Ex-
press database (www.ebi.ac.uk/arrayexpress) with acces-
sion number E-MTAB-4212.
Mass spectrometry and proteomic analyses
Postnuclear cell lysates were prepared and denatured by
using the three denaturation treatment (TRIDENT)
protocol as previously described [43] and were run in a
4–15% polyacrylamide gel [44]. For protein identifica-
tion, the whole lane of the gel was cut in several pieces,
proteins were reduced, alkylated and digested overnight
with bovine trypsin sequencing grade (Roche Applied
Science, Monza, IT) according to a published protocol
[45]. The peptide mixtures were analyzed by nano-
reversed-phase liquid chromatography tandem mass
spectrometry (nRP-LC-MS/MS) using an HPLC Ultim-
ate 3000 (DIONEX, Sunnyvale, CA) connected on line
with a linear Ion Trap (LTQ, Thermo Electron, San Jose,
CA) as described [44]. Data acquisition and analysis was
performed as previously reported [43]. Data were
searched with 1.5 Da and 1 Da tolerance respectively for
precursor and fragment ions. A peptide was considered
legitimately identified when it achieved cross correlation
scores of 1.5 for [M +H]1+, 2.0 for [M + 2H]2+, 2.5 for
[M + 3H]3+, and a peptide probability cut-off for ran-
domized identification of P < 0.001.
Bioinformatic analyses
Genes and proteins lists obtained from the above re-
ported analyses were analyzed using Ingenuity Pathway
Analysis Software (IPA, Ingenuity® Systems, www.ingen-
uity.com) as previously described [26, 46]. In details, it
refers to a proprietary knowledge base (Ingenuity Path-
ways Knowledge Base) annotating molecules, biological
interactions and functional properties. IPA Functional
Analysis on “molecular and cellular functions” category
and Canonical Pathway investigation were performed
calculating the likelihood that the association between
our transcription dataset and a specific function or path-
way is due to random choice, and it is expressed as a
-value calculated using the right-tailed Fisher Exact Test.
In network generation, each differentially expressed
transcript identifier was uploaded and mapped to its cor-
responding object in Ingenuity Knowledge Base toalgorithmically generate molecular networks based on
their connectivity. The networks were scored according
to a numerical value considering the number of dataset
molecules and the network size as well as the total num-
ber of input transcript in the dataset and the total num-
ber of molecules in the Ingenuity Knowledge Base that
could potentially be included in the networks. The net-
work Score is based on the hypergeometric distribution
and is calculated with the right-tailed Fisher Exact Test.
The upstream regulator analysis is based on prior know-
ledge of expected effects between transcriptional regula-
tors and the differentially expressed transcript dataset of
target genes by using information in Ingenuity Know-
ledge Base. For each potential Upstream Regulator
(“UR”) two statistical measures, an overlap p-value and
an activation z-score were computed. The overlap
p-value calls likely URs based on significant overlap be-
tween dataset genes and known targets regulated by a
UR. The activation z-score is used to infer likely activa-
tion states of upstream regulators based on comparison
with a model that assigns random regulation directions.
Under ideal circumstances (the “un-biased” case de-
scribed below) the activation z-score can also be used to
predict upstream regulators independently from the
overlap p-value, based on significant pattern match of
up/down regulation.
Pathways predicted as potentially involved in melan-
oma cell aggressiveness by IPA analyses were further an-
alyzed in GEO database (https://www.ncbi.nlm.nih.gov/
sites/GDSbrowser). Proteins identified by proteomic
analysis were analyzed by the Database for Annotation,
Visualization and Integrated Discovery (DAVID soft-
ware, http://david.abcc.ncifcrf.gov/) that provides a com-
prehensive set of functional annotation tools for
investigators to understand biological meaning behind a
large list of proteins.Validation of the identified molecular pathways
Semi-confluent cells were harvested, plated in medium
with 10% FBS in 6-well plates at 3 × 104 cells/well
density. After 24 h, media were removed, cells were
washed with PBS and medium was replaced with
serum-free medium. Cells, starved for 24 h, were incu-
bated with Infliximab antibody (IFX) (Janssen Biothec,
Inc., USA) at different concentrations (10, 100, and
1000 ng/ml) for 24 h, then cells were washed, har-
vested with trypsin/EDTA and counted with Neubauer
modified chambers. All experiments were carried out
at least 3 times in duplicate. Metalloprotease involve-
ment was assayed by gelatin zymography, MMP-2 ac-
tivity was analyzed in melanoma cells conditioned
medium according to a published procedure [47] with
few modifications [48].
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All experiments were carried out at least three times and
the results were expressed as mean ± standard deviation
(SD). Data were analyzed by the two tails t-Student test.
Differences were considered significant when P < 0.05.
Results
Melanoma cell AGgressiveness score (MAGS): Cell
proliferation, migration and invasion studies
Human cutaneous melanoma cell lines, summarized in
Table 1, were used to investigate and compare their ag-
gressive phenotype. For proliferation assays, cells were
grown in serum-free medium [49] and cell number was
measured at 24 and 48 h of serum deprivation and
expressed as % number vs Time 0 (Fig. 1a).Different
growth rates were observed in the 10 different cell lines;
they were then clustered in three main groups, namely:
high proliferation rate (SK-MEL-110, A375, A375M,
MEL501), low proliferation rate (ME665, SK-MEL-30,
Preyer, SK-MEL-28) and very low proliferation rate (Mel
397 and MeWo) cells (Fig. 1a). The scratch test was then
carried out to measure migration of the 10 melanomaa b
c d
Fig. 1 Characterization of melanoma cell aggressiveness: all the cell lines w
Evaluations and quantifications were assessed by two different operators
serum deprivation, cells were incubated for 24 and 48 h and then they ar
for SK-MEL-110, 57,250 for Mel 397, 46,171 for SK-MEL-30, 57,000 for Preye
for Mewo, 60,500 for Mel 501, 60,500 for Me 665. The data represent the
significance versus control: **P < 0.001; § P < 0.0001). b Migration ability o
performed for 24 h. c Invasion analysis of melanoma cells for 24 h. The in
d Aggressiveness index (MAGS index calculated as reported in Methods),
combination of growth, invasion and migration rates was used to get succell lines, under serum deprivation conditions. Results
are depicted in Fig. 1b. SK-MEL-110, A375 and A375M
cells showed the highest migration rate, while SK-
MEL-28, ME665, SK-MEL-30, MEL501 cells showed
intermediate migration ability; Preyer, MeWo and Mel
397cells showed very low migration potential. Invasion
was then analyzed and A375 and ME665 showed the
highest invasiveness potential while SK-MEL-30 and
Preyer cell lines showed an almost absent invasion abil-
ity (Fig. 1c). Then by combining proliferation, migration
and invasion rates, including the doubling time, the Mel-
anoma cell AGgressiveness Score (MAGS) was calcu-
lated for each cell line, as reported in Methods (Fig. 1d).
Cells with very low MAGS were excluded for further
omics studies, due to difficulties to obtain cell lysates
with a good protein recovery. Therefore, to recapitulate
these differences, two cell lines were selected, namely
A375 as the most aggressive and SK-MEL-28 as the less
aggressive. Interestingly, A375 and SK-MEL-28 are
among the best characterized human melanoma cells
lines in literature even from the mutational and genetic
point of view.ere analysed simultaneously using the same experimental procedures.
in blind. a Growth rate after 24 and 48 h of serum starvation. After
e harvested and counted. Cell counts for each cell line was: 61729
r, 61,333 for A375M, 60,212 for A375, 61,143 for SK-MEL-28, 60,600
mean ± SD of three experiments carried out in triplicate (statistical
f melanoma cell lines. The scratch test on confluent cells were
vasion capability is expressed as number of cells per mm2 of filter.
to cluster melanoma cell lines accordingly to their malignancy: a
h aggressiveness index
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A375 and SK-MEL-28 cells proliferation was then evalu-
ated in the presence of serum; under such conditions
A375 cell line confirmed to grow at a much higher rate
as compared to SK-MEL-28 (Fig. 2a).In addition, serum-
induced invasion of A375 was found to be much higher
than SK-MEL-28 (p < 0.001) (Fig. 2b).The spheroid col-
ony formation capability assay (melanosphere forming
assay) was then carried out as described [35]. As shown
in Fig. 2c and d, A375 cells showed a significantly (p <
0.0001) higher ability to form melanosphere (A375-
spheroids) as primary and secondary spheroids as com-
pared to SK-MEL-28 (SK-MEL-28-spheroids) after both
7 and 14 days of growth, respectively. Total spheroids
were then dissociated into single cell suspension and
counted with similar results. Since this assay allows to
evaluate the stem traits of tumor cells that is related to
resistance to extreme conditions and treatments, these
experiments confirmed that the biological features of the
selected cell lines, under our experimental conditions,
were strikingly different, with the A375 showing a
more aggressive phenotype compared to SK-MEL-28.
Proliferation of the selected cell lines was analyzed in
deprivation serum condition and at three different cell
densities. As depicted in Additional file 1: Figure S1
the two cell lines grow at a similar time-dependenta b
c d
Fig. 2 Characterization of A375 and SK-MEL-28, respectively, the most and the
after 24 h of serum deprivation. A375, under an extreme growing condition, s
Data are expressed as percent of 61,143 cells for SK-MEL-28 and 60,212 cells fo
triplicate. b Invasion ability of melanoma cell lines by Boyden chamber assay.
in particular, a mean of 42 and 5 cell per field were counted respectively). c M
indicates the quantification of total cell number forming A375 and SK-MEL-28rate, at intermediate (intermediate panel) and high
(lower panel) density, while at the lowest cell density
(upper panel) SK-MEL-28 were unable to grow differ-
ently from A375. This suggested that cell-cell signaling
and/or secretory signals related to the cell-density may
be at least in part involved in their aggressive pheno-
type. Interestingly, under low cell density conditions,
SK-MEL-28 cells showed the smallest growth within
the 10 cell lines tested (data not shown). The aggressive
phenotype was also evaluated as sensitivity to serum-
starvation and apoptotic stimuli. A375 confirmed their
higher malignancy since resulted to be more resistant
to both serum-starvation and apoptotic stimuli when
compared to SK-MEL-28 (see Additional file 1: Figure S2).
Transcriptome analysis in differently aggressive
melanoma cell lines
To better investigate the molecular basis of the observed
different growth/invasive phenotype, global gene expres-
sion profile was performed from A375 and SK-MEL-28
cells under the same culturing conditions. Out of the
2973 transcripts found differentially expressed be-
tween the two cell lines, 1513 resulted down-regulated
and 1460 up-regulated in A375 vs SK-MEL-28 (FC
|1.5|, p-value < 0.001) as reported in Additional file 1:
Table S2. The heat map reported in Fig. 3a shows theless aggressive model of human melanoma cell lines. a Cell proliferation
howed a significantly (**P < 0.001) higher growth rate than SK-MEL-28.
r A375 and represent the mean ± SD of three experiments carried out in
A375 were significant able to invade in respect to SK-MEL-28 (**p < 0.001);
icrophotographs showing forming spheroid capability. d The panel
spheroids (§ p < 0.0001)
Fig. 3 Aggressiveness driven de-regulation of transcriptome in melanoma cells behaving and functional analyses of the results. a Heat map of
differentially expressed transcripts in A375 vsSK-MEL-28 human melanoma cells according to log2 AVG signals (left) and fold-change (right). b
Graph showing most significantly enriched molecular functions identified by the IPA analysis. Each histogram reports the –log of the p-value
(Fisher’s exact test) for each molecular function. The straight orange lines mark the significance p-value threshold (0.05)
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ing the two cell lines, highlighting the strong differ-
ence in their gene expression profile. The Ingenuity
Pathway Analysis (IPA) conducted on the differentially
expressed genes in A375 vs SK-MEL-28 cells revealed
that such transcripts are involved in 26 key “molecu-
lar and cellular functions categories” (Fig. 3b and
Additional file 1: Table S3a) such as Cell Death andSurvival, Cellular Growth and Proliferation, Cellular
Development, Cellular Movement, Cellular assembly
and organization, Cell-To-Cell Signaling and Inter-
action. The identified genes fall in several “canonical
pathways” (see Additional file 1: Table 3b) and 25
“top networks” (Additional file 1: Table 3c) mostly
associated with inflammation, cell growth and prolif-
eration and cell movement.
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The IPA was then carried out to predict the upstream
regulators of the genes reported in Fig. 3a. This ana-
lysis predicts, among others, MMP2, TNF and IL-6
(Additional file 1: Figure S3, S4 and S5) as strong up-
stream modulators of the transcriptome changes ob-
served. We then aimed at validating such predictions,
as reported below.
Validation of metalloproteinase 2 (MMP-2) expression and
activity
MMP2 mRNA expression was measured by RT-PCR
and we found to be similar in A375 and SK-MEL-28,
also confirming the transcription profiling data achieved
by a different technological platform (Illumina)(Fig. 4a).
Metalloproteinases activity is regulated by Tissue Inhibi-
tor of Metalloproteinases (TIMPs), therefore TIMPs
mRNA expression was analyzed and was found to be
significantly downregulated in the most aggressive cell
line compared to the less aggressive (p < 0.001) (Fig. 4b).a
b c
Fig. 4 a Weak, not significant, MMP2 mRNA up-regulation in A375 compar
down-regulation of Tissue Inhibitor of Metalloproteinases (TIMP) c The MM
aggressiveness of A375 cells compared to SK-MEL-28As functional validation of these findings, the MMP-2–
related enzymatic activity was then measured under
serum starvation in A375 and SK-MEL-28 conditioned
media by gelatin zymography. The evaluation of the in-
tegrated optical density (IOD) of zymograms confirmed
that MMP-2 activity was 4-fold higher in A375 condi-
tioned media than in SK-MEL-28 conditioned media
(Fig. 4c) (p < 0.001). These data definitely confirm the
strong involvement of MMP-2 enzymatic activity to ex-
plain different aggressiveness in the two melanoma cell
models.
Validation of TNF-α and IL-6 expression
To validate the IPA analysis regarding TNF-αand IL-6,
the expression levels of human cytokines and growth
factors secreted in the A375 and SK-MEL-28 growth
media was measured. Table 2 shows that several cyto-
kines are differently expressed and among these, TNF-α
and IL-6. Namely, PDGF-BB, IL-1β, IL-9, IP-10, IL-8,
IL-1ra and G-CSF resulted significantly down-regulateded to SK-MEL-28. b Highly significant (§§p < 0.00001; §p < 0.0001)
P2 activity evaluated by a gelatin zymography confirming the higher
Table 2 Cytokines Levels in human melanoma cell lines by Luminex analysis
Cytokines SK-MEL-28 (pg/ml/mgProt) A375 (pg/ml/mgProt) p-Value A375 vs SK-MEL-28
PDGF-bb 5.79 ± 2.5 0.00 ± 0.00 0.0491 down-regulated
IL-1β 5.69 ± 3.59 1.98 ± 1.06 0.0001 down-regulated
IL-9 7228.00 ± 1003.00 1310.91 ± 446.08 0.0121 down-regulated
IP-10 83.44 ± 16.52 2.56 ± 07 0.0011 down-regulated
IL-8 322.20 ± 136.72 64.34 ± 13.87 0.0314 down-regulated
IL-1ra 80.35 ± 4.19 33.93 ± 16.17 0.0086 down-regulated
G-CSF 81.68 ± 14.20 22.94 ± 19.73 0.0138 down-regulated
IL-6 1.06 ± 0.04 5.86 ± 2.33 0.0235 up-regulated
IL-12 4.53 ± 2.59 16.38 ± 1.56 0.0008 up-regulated
Eotaxin 0.07 ± 0.02 54.67 ± 8.47 0.0000 up-regulated
RANTES 10.26 ± 1.62 234.04 ± 80.47 0.0015 up-regulated
IFN-γ 29.91 ± 1.23 348.61 ± 62.18 0.0009 up-regulated
TNF-α 1.09 ± 1.78 23.48 ± 3.46 0.0007 up-regulated
VEGF 2021.13 ± 82.71 2929.27 ± 1180,89 0.0037 up-regulated
Cytokines levels up- and down-regulation expressed in A375 compared to SK-MEL-28
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EOTAXIN, RANTES, INF-γ, TNF-α and VEGF were sig-
nificantly up-regulated in A375 as compared to SK-
MEL-28 (see Table 2). IPA analysis was then carried out
on quantitative cytokines expression data. Table 3 reports
the “Disease and Function”, “Pathways” and “Network”
found significantly affected, confirming transcriptomic
data analysis. The molecular mechanisms underlying the
increased TNF pathway were then investigated. The levels
of mRNA-TNF receptors were evaluated as potentiallyTable 3 IPA analysis of quantitative cytokines level expression
IPA ANALYSIS
Disease and Function Cell-To-Cell Signaling and Interaction
Inflammatory Response
Cellular Growth and Proliferation
Tumor Morphology
Cell Signaling
Molecular Transport
Cellular Function and Maintenance
Cell Morphology
Cellular Assembly and Organization
Protein Synthesis
Pathways Colorectal Cancer Metastasis Signaling
PPAR Signaling
LXR/RXR Activation
Dendritic Cell Maturation
Network Cell-To-Cell Signaling and Interaction
Cardiovascular System Development andable to interfere with their expression and found not sig-
nificantly modified (data not shown).
Proteomic analysis by mass spectrometry
To further characterize the molecular profile in the two
melanoma cells lines, deep proteomics analyses were
carried out in A375 and SK-MEL-28 cells extracts ac-
cording to published protocols [44] and followed by
LC-MS/MS. Total number of proteins was calculated ac-
cording to the workflow reported in Fig. 5a. In SK-p-value
8,54E-36
4,1E-34
7,23E-34
8,19E-24
1,18E-20
1,18E-20
1,52E-18
1,48E-12
1,05E-10
7,14E-10
p-value z-score
1,73E-02 2000
4,44E-02 1000
4,13E-02 0,447
4,14E-02 0,378
Score
30
Function/Tissue morphology 15
ab
Fig. 5 Proteomic Analysis a Workflow for the proteomic analysis: proteins analyzed were extracted from cells cultured under serum deprivation
conditions. b Veen diagram summarizing protein specifically identified in A375 and SK-MEL-28. c Functional classification of proteins extracted
from cultured cells and identified by proteomic analysis
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other cell line extract) out of 510 total proteins were
identified, whereas in A375 cells 354 specific proteins
out of 617 total proteins were identified; 263 common
proteins were identified in the two cell lines (Fig. 5b)
and the significantly enriched molecular functions and
pathways identified by David software are reported in
Additional file 1: Table S4.
The identified specific proteins were analyzed by Gene
Ontology and clustering screening through Ingenuity
Pathway Analysis (IPA). Functional annotation analysis
highlighted in A375 the specific presence of several ca-
nonical pathways including VEGF family ligand-receptor
interactions, TNFR1 signaling and IL-1 signaling. Such
IPA analysis of differentially expressed proteins between
A375 and SK-MEL-28 cells identified several “TopDiseases and Functions networks” (Additional file 1:
Table S5a and b)potentially involved in melanoma cell
aggressiveness (e.g. Cancer, Cellular Assembly and
Organization, Cellular Function and Maintenance,
Dermatological Diseases and Conditions, Cell Death
and Survival, Cellular Development, Cellular Growth and
Proliferation, Dermatological Diseases and Conditions,
Cellular Assembly and Organization, Cell Cycle, Cellular
Movement). The cellular functions highlighted by this IPA
analysis on proteomic datasets confirmed that secretory
signals might play a role in melanoma aggressiveness.
Involvement of inflammatory pathways; in vitro
validation
To achieve a functional validation of a crucial role of
TNF-α, cell lines were grown in the presence of increasing
Rossi et al. Journal of Experimental & Clinical Cancer Research          (2018) 37:326 Page 12 of 17doses of Infliximab (IFX), a specific neutralizing TNF anti-
body. Such treatment decreased significantly A375, SK-
MEL-28, SK-MEL-30 and SK-MEL-110 cell proliferation,
in a dose- and time-dependent way (Fig. 6a, b, c, d and e).
The potential effect of IFX-based anti-TNF treatment was
also tested on migratory and invasiveness assays. Results
depicted in Fig. 6e show the effect of IFX treatment on
the aggressiveness of 4 different human melanoma cells,
according to the MAGS scoring system. In all tested cases,
IFX treatment reduces by at least 10 times the computed
score, and, intriguingly, the melanoma cell lines more
sensible to IFX are those showing the highest MAGS
under untreated conditions.In-patients validation of inflammatory pathways
involvement in melanoma compared to nevi
The cytokines or other molecular players found sig-
nificantly up- or down-expressed in more aggressive
melanoma cells compared to less aggressive ones
were investigated in transcriptomic datasets available
online and derived from biopsies of 45 melanoma
patients versus 18 benign nevi (i.e., the GDS1375
dataset in GEO database). The highly significant dif-
ferences and the consensus with the data obtained
on A375 and Sk-MEL-28 cells lines are summarized
in Table 4.a b
c d
e
Fig. 6 An anti-TNF drug (IFX) affects melanoma cell proliferation rate (**p <
on four different cell lines, while panel E compare the IFX-effects on the MDiscussion
One of the most critical issues regarding cutaneous
melanoma is related to its aggressiveness, which was
also related either to mutational and immunological
state or anatomical site [4, 50], or to the intrinsic be-
havior of melanoma cells. To assess the latter point, the
proliferation, migration and invasion abilities of ten hu-
man melanoma cell lines were studied. To summarize
aggressiveness rate of such cancer cells in one unique
parameter, the MAG Score was calculated as a single
number able to recapitulate proliferation, migration
and invasion ability of each melanoma cell. According
to these values, it was possible to classify these human
melanoma cell lines as high and low aggressive cells.
A375 and SK-MEL-28 cells, two of the most studied
human melanoma cells, were chosen as model of different
aggressiveness and malignancy, also confirmed by analyz-
ing in depth their melanosphere forming capabilities.
It should be noted that the in vitro aggressive pheno-
type quantified according to MAGS perfectly matches
the in vivo aggressiveness of the two cell lines [51]. This
suggests that MAGS may have important clinical appli-
cations when patient derived organoids cultures are
available. In these cases, the quantitative approach of
MAGS may evaluate the organoids aggressiveness for
prognostic purposes and to monitor the efficacy of new
drugs under development, or drugs combinations, also0.001; § p < 0.0001). Panel a-d show the anti-proliferative effects of IFX
AG scores calculated for the same cells
Table 4 Validation of involved pathways by in silico / in patient analyses
Pathway name and status in
A375 vs SK-Mel-28
GEO Analysis (Affymetrix)
biopsy of melanomas (n = 45) biopsy of nevi (n = 18) t test (melanomas vs nevi)
TIMP3 (Down-regulated, Illumina) 81.64 ± 9.1 92.56 ± 7.23 p value 0.00006
IL1RA (Down-regulated, Luminex) 60.02 ± 13.34 73.89 ± 12.15 p value 0.00029
VEGFA (Up-regulated, Luminex) 79.31 ± 12.39 60.78 ± 18.15 p value 0.00132
Cytokines found significantly modulated in this study by transcriptomics, proteomics and/or secretome analyses comparing A375 vs SK-MEL-28 cells have been
matched with transcriptomics analyses from patients biopsies (45 melanomas vs 18 nevi). In this Table the consensus is reported
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tify novel intrinsic molecular pathways responsible for
melanoma aggressiveness, the two selected cell lines
were analyzed at transcriptomic, proteomic and secre-
tome analysis level. Ingenuity Pathway Analysis from
these integrated multiomic investigations highlighted the
prominent role of inflammatory response, as well as
metalloproteases and secretion of inflammatory cyto-
kines as potentially involved in determining human mel-
anoma cells aggressive phenotype. In the current study,
melanoma cells were investigated in vitro without any
contact with immune-competent cells, suggesting that
intrinsic pathways are likely to be involved in determin-
ing their aggressive phenotype. IPA analyses of transcrip-
tomic expression profiles indicated TNF, the MMP-2
and IL-6 pathways as the most significantly upstream
regulators, strongly suggesting them as possible key
modulators of the melanoma cell aggressiveness. Several
pathways resulted particularly dragged into cell aggres-
sive phenotype such as Aryl Hydrocarbon Receptor Sig-
naling; OX40 Signaling Pathway, Antigen Presentation
Pathway, Estrogen-mediated S-phase Entry, Cell Cycle,
G1/S Checkpoint Regulation, Vitamin D and seleno-
proteins, known as potentially important in tumor de-
velopment and progression. To confirm the results in-
dicating the important role of TNF, MMP and IL-6,
the proteomic profile by LC-MS/MS analysis of both
cell lines extracts was achieved by applying a multi-
denaturation protocol recently developed to increase
analytical sensitivity of complex mixtures of proteins
[45]. Functional annotation analyses of the collected
data revealed a strong implication in aggressiveness
traits of post-transcriptional modifications, molecular
transport and protein traffic networks and cytokines
signaling pathways. Proliferation rates, calculated under
serum deprivation conditions and in cells seeded at
three different densities, strongly suggested that melan-
oma cell aggressiveness is related to cell density,
highlighting the possibility that a cell-cell interaction
crosstalk and/or the secretion of autocrine signals may
play a role in melanoma aggressiveness and progres-
sion. In the present study, cytokines secretion, evalu-
ated by Luminex technology, showed different levels of
pro-inflammatory cytokines like IL-1β, IL-8 and TNF
both in melanoma cell lysates and in supernatants.TNF-α showed a higher (more than 20-fold increase)
secretion by the most aggressive cell lines. It is note-
worthy that TNF has been found involved in the en-
hancement of tumor invasion partially by upregulating
matrix metalloproteases in human skin [52], therefore
the low transcript levels of TIMP coupled to the in-
creased enzymatic activity of the MMP2 in more ag-
gressive cells, reported in this study, may be a direct
consequence of TNF action, as predicted by IPA. It is
important to note that both transcriptional (Illumina -
Affymetrix) and bioinformatic (IPA) analyses supported
the increased activity of metalloproteases in A375 cells
and that such data were perfectly confirmed by the
MMP2 enzymatic activity measured. These results were
further reinforced by a complementary approach based
on analyses of transcriptomic data from biopsies of
melanoma patients vs benign nevi, with a consensus
within the transcriptomic, proteomic, cytokinomic and
zymography data reported in Figs. 3, 4 and 5, in Ta-
bles 2, 3 and 4 and in Additional file 1. The hypothesis
that TNF-α may be an intrinsic crucial player in melan-
oma growth and aggressiveness was further tested by
inhibiting the TNF secretion through a chimeric mono-
clonal antibody (INFLIXIMAB-IFX). Upon IFX treat-
ment, the proliferation rate was significantly reduced in
3 out of 4 human melanoma cell lines; the highly ag-
gressive A375 cell line exhibited the lower sensitivity to
this drug. The MAG score, based on proliferation, mi-
gration and invasion abilities, showed a marked reduc-
tion that was very striking for the very aggressive
melanoma cell line A375. Recent studies based on
mRNA and protein expression show that several
MMPs, namely MMP-9, MMP-12 MMP-2, MMP-14,
and MMP-19, play a role in melanoma aggressiveness
and consequently may represent useful prognostic bio-
markers [53–55]. The role of TNF-dependent pathways
in melanoma cells growth and malignant phenotype
proposed in the current study confirms previous data
carried out in similar cellular models [56] as well as the
controversial role of TNF in cutaneous melanoma [21].
However, our study suggests, for the first time, a co-
operation between MMP-2 enzymatic activity, mea-
sured by means of zymography approach, and TNF
secretion to define melanoma cells aggressive pheno-
type, as summarized in Fig. 7. The controversial role of
Fig. 7 Cartoon depicting molecular mechanisms potentially underlying the TNF/MMPs activity in determining melanoma cell aggressive phenotype
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growth, has been explained by the ability of tumor cells
to attract TNF-secreting cells through MHC class II
molecules expression [21]. Our study investigates ex-
pression, secretion and function of molecular signals
produced by melanoma cells. A multiomic approach
combined with different cellular functions such as pro-
liferation, migration and invasion, lead to develop a
new quantitative score called MAGS. In fact, in the
present study, for the first time melanoma aggressive-
ness was assayed by simultaneous multiomic and multi-
functional points of view, including enzymatic activities
quantification.
Unexpectedly, MMPs mRNA levels were found to be
similar in both melanoma cell lines, while bioinformatics
analyses indicated that MMPs-related pathways are sig-
nificantly involved in the phenotypic features of A375 cells
(very aggressive) and SK-MEL-28 cells (less aggressive cell
type). Such apparently contradictory finding was explained
by the functional analysis, which confirmed that, despite
similar expression profiles, MMPs enzymatic activity was
strongly and significantly different, likely due to the ob-
served different TIMPs expression. Therefore, our find-
ings indicate that the MMPs pathway considered from a
functional- rather than just the expression-point of
view, may explain, at least in part, the higher A375
cells aggressiveness.
In our in vitro studies, TIMP3 mainly accounts for the
observed reduction of TIMPs expression in A375 com-
pared to SK-MEL-28 cells (Fig. 4), strongly matching thein patients validation reported in Table 4, and according
to previous studies [57].
Further, we found expression of several cyto- and che-
mokines to be strongly different in the two cell types, e.g.
IP-10 more than 32 times down-modulated, RANTES
more than 22 times up-regulated and Eotaxin more than
500 time up-regulated in A375 compared to SK-MEL-28
cells (see Table 2). This signature and the corresponding
specific molecular-balance may represent the scenario
underlying, at least in part, the melanoma aggressiveness.
As an example, a significant increase of eotaxin was re-
ported in humor aqueous samples from uveal melanoma
patients [58], compared to non-melanoma samples, but its
involvement has never been reported in aggressive cutane-
ous melanoma models. Thus, the combined analysis of
transcriptomic, proteomic, secretomic and functional data
may represent a powerful and novel way to further investi-
gate cancer aggressiveness molecular signatures, as shown
in Fig. 7, reporting a simplified model where other import-
ant players for melanoma microenvironment and immune
response are not taken into account (e.g. lymphocytes and
dendritic cells and other molecular signals highly signifi-
cantly modulated in our study). A crucial concept emer-
ging from the present study is the need to approach
complex issues by different and simultaneous functional
points of view. The controversial role of TNF [21], as well
as TIMPs versatility [58], may be better understood in
simplified cellular models carefully characterized in terms
of aggressiveness by applying a functional-quantitative ap-
proach such as the MAGS reported in this study. It is
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apies with anti-TNF drugs is an increase of cancer risk, in-
cluding melanoma, or demyelination [27]. The role played
by growth factors and cytokines in regulating melanoma
cells behaviors was investigated in the past indicating the
presence of a complex network with autocrine and para-
crine effects [59]. Interestingly, when further investigated
at immuno-histochemical level on fresh specimens from
melanocytic nevi and primary cutaneous and metastatic
melanomas, the expression of some inflammatory media-
tors and their receptors was found increased with tumor
progression [19]. The present study confirmed these find-
ings by more quantitative approaches, indicating that mel-
anoma cell itself secretes large amount of TNF-α, IL-6
and other cytokines, triggering a cascade of effects like, for
instance, the increase of MMP2 enzymatic activity, pos-
sibly related to the aggressive phenotype of the cell.
Conclusion
The reported findings indicate i) a novel functional scor-
ing method potentially useful for prognostic purposes
and to better characterize cancer cells from patients-
derived organoids, ii) new mechanisms underlying mel-
anoma cells aggressiveness and novel molecular targets.
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